RB Dowling, CF Rayner, A Rutman, AD Jackson, K Kanthakumar, A Dewar, GW Taylor, PJ Cole, M Johnson and R Wilson
Host Defence Unit, Imperial College of Science, Technology and Medicine, National Heart and Lung Institute, London, United Kingdom.

We have studied the effect of salmeterol on both P. aeruginosa interactions with the mucosa of nasal turbinate organ cultures and on pyocyanin-induced (20 microg/ml) and elastase-induced (100 microg/ml) damage to nasal epithelial cells. Organ cultures were exposed to salmeterol either by preincubation with 4 x 10(-7) M salmeterol for 30 min or by pipetting 20 microl of 4 x 10(-7) M salmeterol onto the organ culture surface immediately prior to bacterial inoculation. Infected organ cultures (8 h) had significantly (p < or = 0.01) increased epithelial damage, and P. aeruginosa was predominantly associated with damaged epithelium and mucus. Salmeterol significantly (p < or = 0.02) reduced epithelial damage caused by infection and the total number of adherent bacteria (p < or = 0.05), but bacterial distribution on the mucosa was unchanged. Nasal epithelial cells incubated with pyocyanin (20 microg/ml) or elastase (100 microg/ml) for 3 h had significantly (p < or = 0.05) increased cytoplasmic blebbing and mitochondrial damage versus control values. Elastase also significantly (p < or = 0.05) increased cell projection and reduced the level of ciliation. Cells preincubated with salmeterol (2 x 10(-7) M) showed a significant reduction in some features of cell damage caused by both toxins, which was inhibited by the beta2-adrenoceptor antagonist propranolol. Our results indicate that salmeterol reduces P. aeruginosa-induced damage to both organ culture and nasal epithelium.

This article has been cited by other articles:

				K. Fragaki, C. Kileztky, C. Trentesaux, J.-M. Zahm, O. Bajolet, M. Johnson, and E. Puchelle Downregulation by a long-acting beta2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial inflammatory mediator production Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L11 - L18. [Abstract] [Full Text] [PDF]

				R. Wilson Treatment of COPD exacerbations: antibiotics Eur. Respir. Rev., September 1, 2005; 14(94): 32 - 38. [Abstract] [Full Text] [PDF]

				R. Wilson Bacteria and Airway Inflammation in Chronic Obstructive Pulmonary Disease: More Evidence Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 147 - 148. [Full Text] [PDF]

				P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]

				M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]

				A. E. Hegab, T. Sakamoto, W. Saitoh, H. H. Massoud, H. M. Massoud, K. M. Hassanein, and K. Sekizawa Polymorphisms of IL4, IL13, and ADRB2 Genes in COPD Chest, December 1, 2004; 126(6): 1832 - 1839. [Abstract] [Full Text] [PDF]

				C. Coraux, C. Kileztky, M. Polette, J. Hinnrasky, J.-M. Zahm, P. Devillier, S. de Bentzmann, and E. Puchelle Airway Epithelial Integrity Is Protected by a Long-Acting {beta}2-Adrenergic Receptor Agonist Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 605 - 612. [Abstract] [Full Text] [PDF]

				A M Middleton, M V Chadwick, A G Nicholson, A Dewar, C Feldman, and R Wilson Investigation of mycobacterial colonisation and invasion of the respiratory mucosa Thorax, March 1, 2003; 58(3): 246 - 251. [Abstract] [Full Text] [PDF]

				Y. Q. O'Malley, M. Y. Abdalla, M. L. McCormick, K. J. Reszka, G. M. Denning, and B. E. Britigan Subcellular localization of Pseudomonas pyocyanin cytotoxicity in human lung epithelial cells Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L420 - L430. [Abstract] [Full Text] [PDF]

				M. Johnson and S. Rennard Alternative Mechanisms for Long-Acting {beta}2-Adrenergic Agonists in COPD Chest, July 1, 2001; 120(1): 258 - 270. [Abstract] [Full Text] [PDF]

				R. L. ZuWallack, D. A. Mahler, D. Reilly, N. Church, A. Emmett, K. Rickard, and K. Knobil Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD Chest, June 1, 2001; 119(6): 1661 - 1670. [Abstract] [Full Text] [PDF]

				G. P. ANDERSON Interactions between Corticosteroids and beta -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S188 - 196. [Full Text] [PDF]

				R. B. Dowling, R. Newton, A. Robichaud, P. J. Cole, P. J. Barnes, and R. Wilson Effect of Inhibition of Nitric Oxide Synthase on Pseudomonas aeruginosa Infection of Respiratory Mucosa In Vitro Am. J. Respir. Cell Mol. Biol., December 1, 1998; 19(6): 950 - 958. [Abstract] [Full Text]

				A. Rutman, R. Dowling, P. Wills, C. Feldman, P. J. Cole, and R. Wilson Effect of Dirithromycin on Haemophilus influenzae Infection of the Respiratory Mucosa Antimicrob. Agents Chemother., April 1, 1998; 42(4): 772 - 778. [Abstract] [Full Text]

				R. B. Dowling, M. Johnson, P. J. Cole, and R. Wilson The Effect of Rolipram, a Type IV Phosphodiesterase Inhibitor, on Pseudomonas aeruginosa Infection of Respiratory Mucosa J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1565 - 1571. [Abstract] [Full Text]